Work

FDA Drug Approval Summary: Bevacizumab (Avastin®) Plus Carboplatin and Paclitaxel as First-Line Treatment of Advanced/Metastatic Recurrent Nonsquamous Non-Small Cell Lung Cancer

Year: 2007

Type: article

Source: The Oncologist

DOI: 10.1634/theoncologist.12-6-713

Authors: Martin H. Cohen, Joe Gootenberg, Patricia Keegan, Richard Pazdur

Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: U.S. Food and Drug Administration

OpenAlex ID: W2125558775

FWCI: 25.26

Cites: 10

Cited by: 406

Related to: 10